An observational study in Preterm Delivery, sponsored by Rea Diagnostics SA. Recruiting at 1 site in Switzerland. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.
Sponsored by Rea Diagnostics SA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Premature Birth with a site in Switzerland — 12 open to participants now, 14 under way, none of them phase 3. Premature Birth · Switzerland.
Among the 34 studies in Premature Birth with a site in Switzerland, this one is the 2nd largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2025, is one of 14 observational ones, reaches primary completion later than 11 of the 13 other live ones, and was the 32nd registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →12 of the 34 studies in Premature Birth with a site in Switzerland are open now. Recruiting first, the newest first:
University of Zurich · Sites in Switzerland
Ages up to 4 wk
Riccardo Pfister · Sites in Switzerland
Ages 14 days–14 days · Healthy volunteers
Henner Hanssen · Sites in Switzerland
Ages 6–12 · Healthy volunteers
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Ages 35 wk–1 yrs · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 120 across 809 observational studies indexed under Premature Birth.
Median enrollment 57 across the 20 interventional studies, 168 across the 14 observational. Of the 19 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 34 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Rea Diagnostics SA as lead sponsor.
Rea Diagnostics SA has 1 study filed under Premature Birth — fewer than ten, so there is no comparison to draw.
2 of the studies in Premature Birth with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07237139University of ZurichPulmonary Volume Changes During Synchonized Noninvasive Positive Pressure Ventilation | 2026-12-31 |
| NCT07307365Rea Diagnostics SAEvaluation of the Clinical Performance of the PremaSure Kit to Assess Premature Delivery Risk in Symptomatic Pregnant Patients | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 34 studies in Premature Birth with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the study is to determine the clinical performance of the PremaSure kit, more precisely to assess whether the PremaSure kit can be used as a self-test to assess the risk of premature delivery in patients showing symptoms of premature delivery. The sensitivity and specificity of the test will be determined using as an outcome the delivery of the patient in the 7/14 days following the test.
The simplified procedure is the following:
Introduction:
Preterm birth is the first cause of death of infants below five years old. One of the key strategies to save preterm babies is to effectively identify women at risk of preterm birth. While current solutions for the assessment of prematurity risk rely on invasive examination performed by medical professional, the PremaSure is intended to be used by lay user, empowering them with a tool to monitor their pregnancy.
Measurement and procedures:
Consenting patient meeting all the inclusion and none of the exclusion critera will be swabbed by a healthcare professional to collect vaginal secretions. A study nurse will perform the test per the test's IFU. Information related to the patient's delivery will be collected after term to evaluate the predictive performance of the PremaSure kit.
Withdrawal and discontinuation:
Participants can withdraw their consent from the study at any time with no consequence for their clinical management. Patients do not have to provide any reason for withdrawing their consent. Patients who wish to withdraw consent for participation in the study, must notify the Principal Investigator by sending an email to or calling the Principal Investigator using the email address/ phone number mentioned in the ICF. Upon receipt of a notification that a patient wishes to withdraw from the study, the Principal Investigator will document the withdrawal in the eCRF and inquire whether the patient consents that already collected data can be kept on record.
Labelling of the device under investigation:
As the IVD device is not commercially available, the labelling shall indicate that the IVD device under investigation is exclusively for use in a performance study. Each device will have a unique identifying number to trace its origin and manufacturing lot.
Accountability of the IVD device:
Upon receipt at the study sites, the kits shall be stored in a secured location and only accessible for team members involved in the study.
Unused, expired or malfunctioning IVD devices shall be returned to the sponsor.
Monitoring plan:
For each of the sub-studies, a separate site initiation visit will be performed after all required approvals are obtained. As part of this visit the staff involved in the study at the study site will be trained on the procedures presented in this protocol. The devices/kits will be shipped to the site after authorization of the study by the Ethics Committee and approval of the required essential documents.
During the study, the monitor will contact and visit the site regularly. The monitor must have access, with reasonable prior notice, to the facilities of the study site and all source documents needed to verify adherence to the protocol as well as the completeness, consistency and accuracy of the data being entered on the eCRFs and other protocol-related documents. Additional checks of the consistency of the source data with the eCRFs will be performed according to the study-specific monitoring plan. The frequency of the monitoring visits will be mainly based on subject recruitment.
The investigator/delegate must ensure that the eCRFs are completed per the eCRF completion guidelines and that all requested subject files (e.g., ICF, medical notes/charts, other documentation verifying the activities conducted at the study) are available for review by the monitor. The required site staff must be available during the monitoring visits and allow necessary time to meet with the monitor to discuss study-related topics and issues.
A close-out visit will be performed for any initiated site.
Data recording:
Electronic Data Capture (EDC) will be used to collect eCRF data. The eCRF, based on RedCap solution, must be completed in a timely manner as per the eCRF completion guidelines.
The principal investigator and delegate site staff member(s) will be trained to enter and edit the data via a secure network, with secure access features (username, password and identification). While entering the data, the principal investigator/delegate will be instantly alerted to data queries by validated programmed checks. Additional review will be performed by the sponsor/monitor on an ongoing basis to check for unexpected patterns in data and for study monitoring. Should discrepant data be detected, a manual query will be issued for clarification of the data. The query will be visible to the principal investigator/delegate via the eCRF. Response/correction by the principal investigator/delegate will be performed directly in the eCRF. All eCRF entered data require must have documented background data which will remain available for the monitor and to health authorities queries and inspections. A complete electronic audit trail will be maintained in the EDC system. The investigator/delegate will approve the data, confirming its accuracy and completion by signing the eCRF electronically (as per US 21 CFR part 11). Data will be stored on secured servers in Switzerland.
Source data verification will be performed by the monitor. In the electronic database the sponsor shall have access to coded data that can be used to monitor patient recruitment and endpoint assessment.
Pregnant patients with symptoms of premature delivery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evaluation of the clinical performance of the PremaSure kit
On the population of patients who have fully completed the study without experiencing a non-spontaneous delivery up to 14 days after the sample collection, we will determine the sensitivity, specificity, accuracy, positive and negative predictive values (PPV and NPV respectively) of the PremaSure test for the identification of pregnant women at risk of pre-term delivery at 7 and 14 days, respectively
Time frame: From enrollment to the delivery of the patient
Estimation of the clinical performance of the PremaSure kit on sub-group population
Estimation of sensitivity and specificity, PPV, NPV and prevalence for the risk of pre-term delivery of sub-groups, defined as any combination of the categories derived from the pregnancy information collected in the context of the present study. The statistical study power may not be attained for each subgroup. The aforementioned values will be determined considering as an outcome a delivery at 7 days, 14 days, or at any duration following the test.
Time frame: From enrollment until the delivery of the patient
Estimation of correlation coefficients between the participant pregnancy information and the outcome of the pregnancy
Time frame: From enrollment until delivery of the patient.
Started Dec 2025 (actual). Primary completion is estimated for Mar 2027, 15 months after the start.
Of 388 observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 61. This study's planned 15 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.